All In Biotech

NDA 021113 · Hikma

Pamidronate Disodium

Pamidronate Disodium · Injection

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Mar 4, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

4 Phase 3, 1 recruiting

FAERS reports

3,394

3,204 serious, 428 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PAMIDRONATE DISODIUM · PAMIDRONATE DISODIUM 30MG/10ML (3MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP1
  • PAMIDRONATE DISODIUM · PAMIDRONATE DISODIUM 90MG/10ML (9MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP1

Clinical trials

Interventional ClinicalTrials.gov studies with "Pamidronate Disodium" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • osteonecrosis534
  • osteonecrosis of jaw435
  • pain421
  • bone disorder173
  • nausea170
  • tooth extraction168
  • fatigue154
  • diarrhoea149
  • malignant neoplasm progression146
  • drug ineffective138
  • pyrexia138
  • infection133

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004134
2005252
2006193
2007151
2008182
2009269
2010399
2011243
2012209
201356
201447
201554
201678
2017100
2018125
2019216
2020185
2021108
202291
2023100
2024105
202560
202637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pamidronate Disodium (Pamidronate Disodium)

2024 spending

$12K

Beneficiaries

97

287 claims

Per beneficiary

$119

$2.08 per unit

View as table
YearSpending
2020$30,773
2021$32,246
2022$30,879
2023$21,537
2024$11,550

Part B: Pamidronate Disodium (Pamidronate Disodium) · HCPCS J2430

2024 spending

$21K

Beneficiaries

281

786 claims

Per beneficiary

$76

2024 ASP limit $11.81 per unit

View as table
YearSpending
2020$70,695
2021$52,084
2022$44,697
2023$33,279
2024$21,383

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.